Vaccination Induced Cellular Immunity – The Novel Therapy Breakthrough against Cancer

Aug. 19, 2016 - PRLog -- SMi Group are delighted to have Farzin Farzaneh, Professor of Molecular Medicine at Kings College London, open the 2016 Cancer Vaccines congress when it returns to central London next month for its 5^th annual show.

Key pioneering work carried out by Professor Farzin Farzaneh and other leading scientists played a crucial role in supporting research for a new vaccine aimed at enabling the immune system to fight against advanced cancer. Earlier this year, the vaccine began trials in London and Guildford. The (VAPER) trial which is expected to last 18-24 months, will test potential benefits of the vaccination programme, any side effects associated with it and the impact of this treatment on patients' quality of life.*

In his exclusive keynote address, Professor Farzin Farzaneh will be providing attendees of the conference with progressive insight into the most prominent immune therapy strategies including therapeutic antibodies, checkpoint blockades and CAR T Cells. Combination of high throughput genomics, identification of cancer specific neo-antigens, and new adjuvants for the induction of therapeutic, cancer specific, cellular immunity, will also be discussed.

A snap shot of those confirmed include

4-Antibody AG, Abzena, Amal Therapeutics, Antwerp University, BioNTech AG, Boehringer Ingelheim, Cancer Research UK, ccit-denmark, Center into Diseases for Public Health Research, DanDrit Biotech, Exicure, Genentech, ImmunoCellular Therapeutics, IO Biotech, Merck Research Laboratories, NHS Greater Glasgow and Clyde, Northwest Biotherapeutics, Nottingham Trent University, Oxford BioMedica, ProImmune, Shionogi, Translational Oncology (TRON), Vaccinogen and more.

Further information and a full speaker line-up is available at http://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines

Cancer Vaccines 2016
5th annual conference: 21st & 22nd September
Pre-Conference interactive workshops: 20th September
http://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines

Contact information:
For media enquires contact Teri Arri on +44 (0)20 7827 6162 or email tarri@smi-online.co.uk
To sponsor the event, contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
To contact the sales team, call Matthew Apps on +44 (0)20 7827 6093 or email mapps@smi-online.co.uk

---END ---

About SMi:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

*Source: http://medicalxpress.com/news/2016-03-trial-cancer-vaccine.html